Acorah Software Products - Accounts Production 19.2.450 false true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 12651713 Mr J E Powell Dr P Finigan true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12651713 2024-12-31 12651713 2025-12-31 12651713 2025-01-01 2025-12-31 12651713 frs-core:CurrentFinancialInstruments 2025-12-31 12651713 frs-core:Non-currentFinancialInstruments 2025-12-31 12651713 frs-core:ComputerEquipment 2025-12-31 12651713 frs-core:ComputerEquipment 2025-01-01 2025-12-31 12651713 frs-core:ComputerEquipment 2024-12-31 12651713 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-01-01 2025-12-31 12651713 frs-core:FurnitureFittings 2025-12-31 12651713 frs-core:FurnitureFittings 2025-01-01 2025-12-31 12651713 frs-core:FurnitureFittings 2024-12-31 12651713 frs-core:OtherResidualIntangibleAssets 2025-12-31 12651713 frs-core:OtherResidualIntangibleAssets 2025-01-01 2025-12-31 12651713 frs-core:OtherResidualIntangibleAssets 2024-12-31 12651713 frs-core:PlantMachinery 2025-12-31 12651713 frs-core:PlantMachinery 2025-01-01 2025-12-31 12651713 frs-core:PlantMachinery 2024-12-31 12651713 frs-core:CapitalRedemptionReserve 2025-12-31 12651713 frs-core:SharePremium 2025-12-31 12651713 frs-core:ShareCapital 2025-12-31 12651713 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 12651713 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 12651713 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 12651713 frs-bus:SmallEntities 2025-01-01 2025-12-31 12651713 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 12651713 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 12651713 1 2025-01-01 2025-12-31 12651713 frs-core:CostValuation 2024-12-31 12651713 frs-core:CostValuation 2025-12-31 12651713 frs-core:ProvisionsForImpairmentInvestments 2024-12-31 12651713 frs-core:ProvisionsForImpairmentInvestments 2025-12-31 12651713 frs-bus:Director1 2025-01-01 2025-12-31 12651713 frs-bus:Director2 2025-01-01 2025-12-31 12651713 frs-countries:EnglandWales 2025-01-01 2025-12-31 12651713 2023-12-31 12651713 2024-12-31 12651713 2024-01-01 2024-12-31 12651713 frs-core:CurrentFinancialInstruments 2024-12-31 12651713 frs-core:Non-currentFinancialInstruments 2024-12-31 12651713 frs-core:CapitalRedemptionReserve 2024-12-31 12651713 frs-core:SharePremium 2024-12-31 12651713 frs-core:ShareCapital 2024-12-31 12651713 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31
Registered number: 12651713
UK Vein Clinic Group Limited
Financial Statements
For The Year Ended 31 December 2025
Fairman Harris
1 Landor Road
London
SW9 9RX
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—6
Page 1
Balance Sheet
Registered number: 12651713
2025 2024
Notes £ £ £ £
FIXED ASSETS
Intangible Assets 4 51,513 -
Tangible Assets 5 154,312 154,728
Investments 6 29,857 29,857
235,682 184,585
CURRENT ASSETS
Stocks 7 - 88,403
Debtors 8 1,131,326 3,314,039
Cash at bank and in hand 319,070 405,927
1,450,396 3,808,369
Creditors: Amounts Falling Due Within One Year 9 (139,781 ) (62,950 )
NET CURRENT ASSETS (LIABILITIES) 1,310,615 3,745,419
TOTAL ASSETS LESS CURRENT LIABILITIES 1,546,297 3,930,004
Creditors: Amounts Falling Due After More Than One Year 10 (1,500,000 ) (3,781,717 )
PROVISIONS FOR LIABILITIES
Deferred Taxation (26,848 ) (38,682 )
NET ASSETS 19,449 109,605
CAPITAL AND RESERVES
Called up share capital 11 1,990 1,990
Share premium account 303 303
Capital redemption reserve (24,990 ) (24,990 )
Profit and Loss Account 42,146 132,302
SHAREHOLDERS' FUNDS 19,449 109,605
Page 1
Page 2
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr J E Powell
Director
2 July 2026
The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
UK Vein Clinic Group Limited is a private company, limited by shares, incorporated in England & Wales, registered number 12651713 . The registered office is Lower Ground Floor, 150 Harley Street, London, W1G 7LQ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are start up cost. It is amortised to the profit and loss account over its estimated economic life of 30 years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Plant & Machinery 20 % Straight Line
Fixtures & Fittings 20 % Straight Line
Computer Equipment 20 % Straight Line
2.5. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.6. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
...CONTINUED
Page 3
Page 4
2.6. Taxation - continued
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 43 (2024: 36)
43 36
4. Intangible Assets
Other
£
Cost
As at 1 January 2025 -
Additions 52,537
As at 31 December 2025 52,537
Amortisation
As at 1 January 2025 -
Provided during the period 1,024
As at 31 December 2025 1,024
Net Book Value
As at 31 December 2025 51,513
As at 1 January 2025 -
5. Tangible Assets
Plant & Machinery Fixtures & Fittings Computer Equipment Total
£ £ £ £
Cost
As at 1 January 2025 1,157 9,472 315,013 325,642
Additions 37,387 - 51,305 88,692
As at 31 December 2025 38,544 9,472 366,318 414,334
Depreciation
As at 1 January 2025 280 996 169,638 170,914
Provided during the period 260 983 87,865 89,108
As at 31 December 2025 540 1,979 257,503 260,022
Net Book Value
As at 31 December 2025 38,004 7,493 108,815 154,312
As at 1 January 2025 877 8,476 145,375 154,728
Page 4
Page 5
6. Investments
Other
£
Cost
As at 1 January 2025 29,857
As at 31 December 2025 29,857
Provision
As at 1 January 2025 -
As at 31 December 2025 -
Net Book Value
As at 31 December 2025 29,857
As at 1 January 2025 29,857
7. Stocks
2025 2024
£ £
Stock - 88,403
8. Debtors
2025 2024
£ £
Due within one year
Prepayments and accrued income 117,784 132,019
Other debtors 17,600 6,200
Directors' loan accounts 31,567 -
166,951 138,219
Due after more than one year
Amounts owed by group undertakings 964,375 3,175,820
1,131,326 3,314,039
9. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Trade creditors 150 (294 )
Corporation tax 10,654 -
Other taxes and social security 58,202 47,993
Other creditors 143 9,451
Accruals and deferred income 56,532 5,800
Directors' loan accounts 14,100 -
139,781 62,950
Page 5
Page 6
10. Creditors: Amounts Falling Due After More Than One Year
2025 2024
£ £
Bank loans 1,500,000 1,500,000
Amounts owed to group undertakings - 2,281,717
1,500,000 3,781,717
11. Share Capital
2025 2024
£ £
Allotted, Called up and fully paid 1,990 1,990
12. Directors Advances, Credits and Guarantees
Included within Debtors are the following loans to directors:£31,567.
The above loan is unsecured, interest free and repayable by 1st of October 2025.
13. Related Party Transactions
Dr Newmans Clinic Limited - Intercompany balance: Dr £523,509, (2024 Dr £2,566,158)
UK Vein Clinic Ltd - Intercompany balance: Dr £440,865, (2024 Cr £2,281,717)
Uk Vein Clinic (Thames Valley) Ltd - Intercompany balance: £Nil, (2024 Dr £424,578)
Uk Vein Clinic Cambridge Ltd - Intercompany balance: £Nil, (2024 Dr £96,935)
Uk Vein Clinic Surrey Ltd - Intercompany balance: £Nil (2024 Dr £88,149)
14. Ultimate Controlling Party
There is no company's controlling party, due to shareholders holding equal amount of shares.
Page 6